In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.
Definitively diagnosed adult RDD patients;
Aged between 18 and 80 years;
Treatment-naive or refractory/relapsed;
ECOG performance status score ≤ 2;
Subjects who have undergone major surgery within 4 weeks prior to the first dose of the study;
Subjects who have received radiotherapy within 4 weeks prior to the first dose of the study;
Subjects with a history of myocardial infarction within the past year;
Patients with New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, or a history of NYHA Class 3 or 4 congestive heart failure;